Abstract | BACKGROUND AND AIMS: METHODS: The study was comprised of 99 patients with NAFLD and 75 healthy controls. Serum VEGF and sVEGFR-1 concentrations were measured using commercially available enzyme-linked immunosorbent assays. RESULTS: Serum VEGF levels did not differ in patients with NAFLD (1882 ± 942 pg/mL) compared with healthy controls (1985 ± 945 pg/mL, p = 0.42). However, compared with healthy subjects, levels of sVEGFR-1 were significantly lower in patients with NAFLD (1.59 ± 0.58 ng/mL vs. 1.16 ± 0.34 ng/mL, respectively, p <0.001). After allowance for potential confounders, serum sVEGFR-1 levels retained their independent significance as a predictor of liver fibrosis in patients with NAFLD (β = -0.19; t = -1.81, p <0.05). CONCLUSIONS: Our results show that patients with biopsy-proven NAFLD have a significant reduction in serum sVEGFR-1 concentrations that predict the degree of liver fibrosis, independent of potential confounders.
|
Authors | Yusuf Yilmaz, Oya Yonal, Ramazan Kurt, Yesim Ozen Alahdab, Osman Ozdogan, Cigdem Ataizi Celikel, Engin Ulukaya, Nese Imeryuz, Cem Kalayci, Erol Avsar |
Journal | Archives of medical research
(Arch Med Res)
Vol. 42
Issue 1
Pg. 38-43
(Jan 2011)
ISSN: 1873-5487 [Electronic] United States |
PMID | 21376261
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor Receptor-1
|
Topics |
- Adult
- Biopsy
- Fatty Liver
(blood, pathology)
- Female
- Humans
- Liver
(pathology)
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
- Vascular Endothelial Growth Factor A
(blood)
- Vascular Endothelial Growth Factor Receptor-1
(blood)
|